Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coxsackievirus A21 + mitomycin C
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Administration
- Intravesical
01
Overview
**Coxsackievirus A21 + mitomycin C** is an investigational combination therapy under evaluation for the treatment of non-muscle invasive bladder cancer (NMIBC). *Coxsackievirus A21* (CVA21), marketed as Cavatak, is an oncolytic virus that targets and lyses cancer cells expressing ICAM-1 (intercellular adhesion molecule 1) and decay-accelerating factor (DAF), leading to direct tumor cell killing and potentially enhancing antitumor immunity. *Mitomycin C* (MMC) is an antineoplastic antibiotic and alkylating agent that functions primarily by cross-linking DNA and inhibiting its synthesis. When used together, low-dose mitomycin C increases surface expression of ICAM-1 on tumor cells, significantly enhancing the ability of CVA21 to infect, replicate within, and destroy those tumor cells. This synergistic effect has been demonstrated both in cell lines and ex vivo tumor samples, supporting ongoing clinical trial development for this combination in NMIBC[1][3][5][7][9].
- Brand names
- Cavatak (for coxsackievirus A21)Mutamycin (for mitomycin C)Jelmyto (for mitomycin C)Mitosol (for mitomycin C)
- Other names
- coxsackievirus A21 + mitomycin CCVA21 + MMC
02
Targets
DNACD55 (Complement decay-accelerating factor)ICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on coxsackievirus A21 + mitomycin C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coxsackievirus A21 + mitomycin C.